🫁 Pulmonary Tuberculosis Chemotherapy Regimen
This tool gives the standardized pulmonary tuberculosis chemotherapy regimen by new, retreatment, or drug-resistant status, with principles and monitoring.
Clinical takeaway
Resistance screening before treatment is emphasized so retreatment and drug-resistant cases are never managed by blindly reusing the first-line regimen. (original synthesis · not guideline verbatim)
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to select the regimen — 2HRZE/4HR for new susceptible TB, susceptibility-guided retreatment, and an individualized MDR regimen with referral.
How it works
New susceptible → 2HRZE/4HR (6 months) with DOT. Retreatment → susceptibility-guided (classically streptomycin-containing). RR/MDR → individualized regimen (bedaquiline, linezolid) by susceptibility, specialist-managed.
Key points
- Resistance screening before treatment is emphasized so retreatment and drug-resistant cases are never managed by blindly reusing the first-line regimen. (original synthesis · not guideline verbatim)
- DOT and full-course adherence underpin all regimens.
- Monitoring covers hepatotoxicity (H/R/Z), vision/color vision (E), and uric acid (Z).
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Treatment category | New (susceptible) |
|---|
→Regimen2HRZE/4HR (6 months)
- Recommended regimen：2HRZE/4HR: intensive phase 2 months (isoniazid H + rifampin R + pyrazinamide Z + ethambutol E), continuation phase 4 months (HR), 6 months total
- Principles：early, combined, appropriate dose, regular, complete; single daily dose, regular and complete, with directly observed therapy (DOT) throughout; sputum at end of month 2 and 5; if still positive at month 2, extend the intensive phase by 1 month
- Monitoring：Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly
| Treatment category | Rifampin-resistant / multidrug-resistant (RR/MDR) |
|---|
→RegimenMDR regimen (specialist)
- Recommended regimen：Rifampin-resistant/multidrug-resistant (RR/MDR-TB): do not use the standard first-line regimen, build an individualized longer or shorter MDR regimen per susceptibility (including bedaquiline, linezolid, etc.), refer to a TB specialist
- Principles：early, combined, appropriate dose, regular, complete; needs TB-specialist and standardized management (DOT, adverse-event monitoring, social support)
- Monitoring：Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly
Frequently asked questions
- What is Pulmonary Tuberculosis Chemotherapy Regimen?
- This tool gives the standardized pulmonary tuberculosis chemotherapy regimen by new, retreatment, or drug-resistant status, with principles and monitoring.
- How is Pulmonary Tuberculosis Chemotherapy Regimen calculated? What is the core formula?
- New susceptible → 2HRZE/4HR (6 months) with DOT. Retreatment → susceptibility-guided (classically streptomycin-containing). RR/MDR → individualized regimen (bedaquiline, linezolid) by susceptibility, specialist-managed.
- When is Pulmonary Tuberculosis Chemotherapy Regimen used?
- Use to select the regimen — 2HRZE/4HR for new susceptible TB, susceptibility-guided retreatment, and an individualized MDR regimen with referral.
- What are the key clinical points for Pulmonary Tuberculosis Chemotherapy Regimen?
- Resistance screening before treatment is emphasized so retreatment and drug-resistant cases are never managed by blindly reusing the first-line regimen. (original synthesis · not guideline verbatim) DOT and full-course adherence underpin all regimens. Monitoring covers hepatotoxicity (H/R/Z), vision/color vision (E), and uric acid (Z).
- What are the limits and cautions when using Pulmonary Tuberculosis Chemotherapy Regimen?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Pulmonary Tuberculosis Chemotherapy Regimen calculated in practice? Can you show a worked example?
- Inputs: Treatment category New (susceptible) → Result: Regimen 2HRZE/4HR (6 months)（Recommended regimen: 2HRZE/4HR: intensive phase 2 months (isoniazid H + rifampin R + pyrazinamide Z + ethambutol E), continuation phase 4 months (HR), 6 months total, Principles: early, combined, appropriate dose, regular, complete; single daily dose, regular and complete, with directly observed therapy (DOT) throughout; sputum at end of month 2 and 5; if still positive at month 2, extend the intensive phase by 1 month, Monitoring: Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly） Inputs: Treatment category Rifampin-resistant / multidrug-resistant (RR/MDR) → Result: Regimen MDR regimen (specialist)（Recommended regimen: Rifampin-resistant/multidrug-resistant (RR/MDR-TB): do not use the standard first-line regimen, build an individualized longer or shorter MDR regimen per susceptibility (including bedaquiline, linezolid, etc.), refer to a TB specialist, Principles: early, combined, appropriate dose, regular, complete; needs TB-specialist and standardized management (DOT, adverse-event monitoring, social support), Monitoring: Resistance screening (molecular testing) before and during treatment; monitor liver function (H/R/Z), vision and color vision (E), uric acid (Z), sputum conversion; manage adverse drug reactions promptly）